Vland Biotech released its 2026 interim report on August 27. During the reporting period, the company achieved operating revenue of 710 million yuan, up 8.80% year on year. Net profit attributable to the parent company was 38.56 million yuan, up 44.33% year on year. Net profit after deducting non-recurring items was 22.164 million yuan, up 38.51% year on year. Net cash flow from operating activities reached 56.294 million yuan, a sharp year-on-year increase of 455.96%. Leveraging the coordinated strength of its three core businesses, enzyme preparations, probiotics, and animal health products, the company's overseas revenue reached 96.325 million yuan, up 66.41% year on year, becoming an important engine for performance growth. Research and development investment was 62.034 million yuan, accounting for 8.74% of revenue. The book value of long-term equity investments fell 93.06%, due to the switch to the cost method for accounting for ADM Vland Biotech Shandong Company Limited.
Qingdao Vland Biotech Co LtdVland Biotech's 2026 interim report shows net profit up 44.33% and operating cash flow up 455.96% year on year.
ADM Vland Biotech Shandong is only mentioned as the entity whose accounting method switch cut long-term equity investment book value 93.06%.
